Filters: author is Ijzerman [Clear All Filters]
- 2005
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain,
Eur J Pharmacol, vol. 514, no. 2-3, pp. 131-40. DOI
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents,
Eur J Pharm Sci, vol. 24, no. 1, pp. 59-66. DOI
- 2004
Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat,
Eur J Pharmacol, vol. 504, no. 1-2, pp. 7-15. DOI
- 2003
Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships,
Eur J Pharm Sci, vol. 20, no. 3, pp. 347-56. DOI
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives,
Eur J Pharm Sci, vol. 19, no. 1, pp. 13-22. DOI
Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1307-13. DOI
- 1999
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo,
J Pharmacol Exp Ther, vol. 290, no. 2, pp. 702-9.
- 1998
Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action,
J Pharmacol Exp Ther, vol. 287, no. 1, pp. 21-30.
- 1997
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo,
J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.
Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists,
J Pharmacokinet Biopharm, vol. 25, no. 6, pp. 673-94.
- 1996
Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo,
Br J Pharmacol, vol. 118, no. 2, pp. 369-77.
Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo,
J Pharmacol Exp Ther, vol. 279, no. 3, pp. 1439-46.
- 1995
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine,
J Pharmacol Exp Ther, vol. 275, no. 1, pp. 245-53.
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats,
J Pharmacol Exp Ther, vol. 273, no. 1, pp. 405-14.
- 1994
Assessment of the enantiomeric purity of R- and S-N6-phenylisopropyladenosine (PIA): implications for adenosine receptor subclassification,
Naunyn Schmiedebergs Arch Pharmacol, vol. 350, no. 1, pp. 109-12.
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat,
J Pharmacol Exp Ther, vol. 268, no. 2, pp. 616-24.


